Patents by Inventor Juan Vergez
Juan Vergez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8637080Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: GrantFiled: June 25, 2008Date of Patent: January 28, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató, KFTInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Patent number: 8591947Abstract: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.Type: GrantFiled: September 24, 2012Date of Patent: November 26, 2013Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Juan A. Vergez, Marcelo A. Ricci
-
Patent number: 8574626Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: GrantFiled: July 18, 2012Date of Patent: November 5, 2013Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Juan A. Vergez, Joaquina Faour, Ana C. Pastini, Guido S. Bigatti, Glenn A. Meyer, Ethel C. Feleder, Marcelo A. Ricci, Marcelo A. Coppari, Marcelo F. Befumo
-
Publication number: 20130115249Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: ApplicationFiled: July 18, 2012Publication date: May 9, 2013Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Juan A. VERGEZ, Joaquina FAOUR, Ana C. PASTINI, Guido S. BIGATTI, Glenn A. MEYER, Ethel C. FELEDER, Marcelo A. RICCI, Marcelo A. COPPARI, Marcelo F. BEFUMO
-
Publication number: 20130108693Abstract: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.Type: ApplicationFiled: September 24, 2012Publication date: May 2, 2013Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Juan A. VERGEZ, Marcelo A. RICCI
-
Patent number: 8329217Abstract: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.Type: GrantFiled: February 15, 2006Date of Patent: December 11, 2012Assignee: Osmotica Kereskedelmi es Szolgaltato KftInventors: Juan A. Vergez, Marcelo A. Ricci
-
Patent number: 8252331Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.Type: GrantFiled: November 28, 2005Date of Patent: August 28, 2012Assignee: Osmotica Kereskedelmi és Szolgáltató, KFTInventors: Glenn A. Meyer, Ethel C. Feleder, Marcelo A. Ricci, Marcelo A. Coppari, Marcelo F. Befumo, Joaquina Faour, Juan A. Vergez
-
Patent number: 8241667Abstract: A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided.Type: GrantFiled: December 29, 2005Date of Patent: August 14, 2012Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Juan A. Vergez, Marcelo A. Ricci
-
Patent number: 8029822Abstract: The present invention provides a simple and improved osmotic device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use. One or both of the passageways optionally increases in size during use of the osmotic device. The preformed passageway and/or the second passageway increase the release rate of the active agent, enable the release of large particles containing active agent, and/or enable the release of active agents that are substantially insoluble in the environment of use. By virtue of the in situ formation of the second aperture, the device is able to release a greater overall percentage of active agent than it would release in absence of the second aperture.Type: GrantFiled: May 21, 2004Date of Patent: October 4, 2011Assignee: Osmotica Kereskedelmi és Seolgáltató KFTInventors: Joaquina Faour, Juan A Vergez
-
Publication number: 20090004229Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicant: OSMOTICA COSTA RICA SOCIEDAD ANONIMAInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Publication number: 20080175909Abstract: The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of symptoms associate with Alzheimer's disease and/or Parkinson's disease patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.Type: ApplicationFiled: October 10, 2007Publication date: July 24, 2008Applicant: OSMOTICA CORP.Inventors: Juan A. VERGEZ, Joaquina FAOUR, Marcelo A. RICCI, Ana C. PASTINI
-
Publication number: 20070275060Abstract: The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally further comprises an immediate or rapid release composition of carbidopa and/or levodopa. The extended release composition in the tablet excludes a release rate-controlling polymer, and a release rate-controlling coating; however, the release of the carbidopa and/or levodopa is independently optionally delayed for a lag time. The invention also provides a tablet having a extended release form of levodopa and a rapid or immediate release form of carbidopa. A tablet can contain levodopa present in extended release form and rapid or immediate release form, and carbidopa present in extended release form and rapid or immediate release form. The tablet is used to treat Parkinson's disease and other movement related disorders, diseases or syndromes.Type: ApplicationFiled: August 2, 2006Publication date: November 29, 2007Applicant: OSMOTICA COSTA RICA SOCIEDAD ANONIMAInventors: Marcelo Befumo, Marcelo Ricci, Ethel Feleder, Glenn Meyer, Joaquina Faour, Juan Vergez
-
Patent number: 7208176Abstract: The present invention provides a dual release solid dosage form containing a first composition that releases a neuraminidase inhibitor, such as oseltamivir, zanamivir, or peramivir, in a controlled manner and a second composition that releases an H1 antagonist in a rapid and/or immediate manner. A wide range of H1 antagonist antihistamines, especially fexofenadine and loratadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. The device is useful for the treatment of respiratory congestion and other viral infection associated symptoms.Type: GrantFiled: July 15, 2003Date of Patent: April 24, 2007Assignee: Osmotica Corp.Inventors: Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci
-
Publication number: 20060204578Abstract: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.Type: ApplicationFiled: February 15, 2006Publication date: September 14, 2006Inventors: Juan Vergez, Marcelo Ricci
-
Publication number: 20060177510Abstract: A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided.Type: ApplicationFiled: December 29, 2005Publication date: August 10, 2006Inventors: Juan Vergez, Marcelo Ricci
-
Publication number: 20060177507Abstract: The present invention provides a simple and improved osmotic device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use. One or both of the passageways optionally increases in size during use of the osmotic device. The preformed passageway and/or the second passageway increase the release rate of the active agent, enable the release of large particles containing active agent, and/or enable the release of active agents that are substantially insoluble in the environment of use. By virtue of the in situ formation of the second aperture, the device is able to release a greater overall percentage of active agent than it would release in absence of the second aperture.Type: ApplicationFiled: January 13, 2006Publication date: August 10, 2006Inventors: Joaquina Faour, Juan Vergez
-
Publication number: 20060159763Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.Type: ApplicationFiled: November 28, 2005Publication date: July 20, 2006Inventors: Glenn Meyer, Ethel Feleder, Marcelo Ricci, Marcelo Coppari, Marcelo Befumo, Joaquina Faour, Juan Vergez
-
Publication number: 20060063810Abstract: The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and/or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.Type: ApplicationFiled: August 30, 2005Publication date: March 23, 2006Inventors: Juan Vergez, Alan Lanier, Ethel Feleder, Glenn Meyer, Marcelo Ricci, Joaquina Faour
-
Publication number: 20060062851Abstract: The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of depression in Alzheimer's disease and/or Parkinson's disease patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.Type: ApplicationFiled: June 22, 2005Publication date: March 23, 2006Inventors: Juan Vergez, Joaquina Faour, Marcelo Ricci, Ana Pastini
-
Patent number: 7008641Abstract: The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-psychotic agent in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather compression-coated onto the device. The device with spray-coated external core is smaller and easier to swallow than the similar device having a compression-coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.Type: GrantFiled: February 26, 2003Date of Patent: March 7, 2006Assignee: Osmotica Corp.Inventors: Joaquina Faour, Juan Vergez